, a biotechnology company whose backers include investment groups led by Paul Allen and Bill Gates, filed with the
Securities and Exchange Commission
for an initial public offering of $75 million of its common stock.
The company, which is based in Bothell, Wash., is involved in biotechnology research and drug development, focusing specifically on treating cancer patients. Seattle Genetics plans to seek a
listing for its securities.
CIBC World Markets
Banc of America Securities
are handling the IPO.